There is a need for continued efforts to improve minority enrollment in clinical trials. The importance of real-world evidence to complement trial data is growing. A combined approach should use trial ...

Panelists discuss how new molecular imaging technology offers potential to better risk stratify patients eligible for adjuvant pembrolizumab after surgery, potentially identifying those who have ...

Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic ...

A multistakeholder approach is required (patients, communities, clinicians, payers, industry). Community outreach initiatives are essential for building trust. A comprehensive approach is needed to ...

A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC) A 75% negative predictive value Important observation that non–clear cell positive cases were still malignant A ...

Recent data show that the use of minimally invasive surgical therapies (MISTs) for the management of benign prostatic hyperplasia (BPH) is increasing among men aged 50 to 65. 1 Overall, MIST ...

Urologists from Cleveland Clinic recently collaborated across borders to perform the world’s first remotely conducted robot–assisted high-intensity focused ultrasound (HIFU) focal therapy procedure ...

In the following interview, co-author and panel member Benjamin M. Brucker, MD, provides a detailed walkthrough of these guidelines and discusses their practical implications for clinicians.He ...

Discrepancies between the 2 training pathways extend beyond residency, with differences in both practice patterns and physician demographics. Research across various specialties and with diverse ...

Computational Histology Artificial Intelligence (CHAI) biomarkers demonstrated the ability to prognosticate outcomes for patients with high-grade (HG) Ta non–muscle-invasive bladder cancer (NMIBC), ...

"At the end of the day, it's going to be unlikely that we're going to use a single therapy for all of our patients," says Vignesh T. Packiam, MD. There has been an explosion of treatment options in ...

64 Cu-SAR-Bombesin works by targeting the gastrin-releasing peptide receptor (GRPR), which is expressed in several malignancies, including prostate cancer, the company noted. "The SABRE trial ...